Lobbying Information
Subject Matters
- Aboriginal Affairs
- Agriculture
- Internal Trade
- International Trade
- Regional Development
- Environment
- Taxation and Finance
- Industry
- Justice and Law Enforcement
- Intellectual Property
- Constitutional Issues
- Consumer Issues
- International Relations
- Health
- Science and Technology
Subject Matter Details
Politique ou Programme
- Canada's Access to Medicines Regime (CAMR) with regard to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
- Canada's Food and Consumer Safety Action Plan with regard to ensuring that patient safety is a priority in a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.
- Cost Recovery Initiative, ensuring a framework where user fees adequately fund a safe and efficient review process.
- National Pharmaceutical Strategy (NPS) with regard to ensuring development or implementation of any policies or programs include consultations with all affected stakeholders and focus on bettering access to medicines for Canadians.
- Patented Medicines Price Review Board (PMPRB) with regard to ensuring that PMPRB Guidelines, Policies and Procedures reflect PMPRB mandate to ensure that prices charged for patented medicines in Canada are not excessive and that potential changes consider impact to the pharmaceutical industry.
- Science and Technology (S&T) Strategy with regard to ensuring that the implementation of that strategy encourages a public policy environment that attracts business investment in innovation and enhances the ability of Canadian industry to compete internationally.
- Scientific Research and Experimental Development (SR&ED) Tax Incentive Program with regard to expansion of eligible expenditures to recognize the impact on innovation and the research and development (R&D) investment by the pharmaceutical industry in Canada.
Politique ou Programme, Règlement
- Blueprint for Renewal with regard to ensuring a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.
Règlement
- Patented Medicine Prices Review Board (PMPRB) with regard to ensuring guidelines also provide incentives for innovation through research and development in addition to PMPRB mandate of protection from excessive prices.
- Patented Medicines (Notice Of Compliance) Regulations with regard to ensuring that Canada's intellectual property (IP) laws and regulations are internationally competitive and continue to provide a stable and predictable business environment to encourage continued pharmaceutical investment in Canada.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Aboriginal Affairs and Northern Development Canada
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Canadian International Development Agency (CIDA)
-
Public Health Agency of Canada (PHAC)
-
Atlantic Canada Opportunities Agency (ACOA)
-
Canada Revenue Agency (CRA)
-
Agriculture and Agri-Food Canada (AAFC)
-
Veterans Affairs Canada (VAC)
-
Privy Council Office (PCO)
-
Federal Office of Regional Development – Quebec (FORD[Q])
-
Prime Minister's Office (PMO)
-
House of Commons
-
Patented Medicine Prices Review Board (PMPRB)
-
Natural Sciences and Engineering Research Council (NSERC)
-
National Research Council (NRC)
-
National Defence (DND)
-
Members of the House of Commons
-
Western Economic Diversification Canada (WD)
-
Environment Canada
-
Finance Canada (FIN)
-
Royal Canadian Mounted Police (RCMP)
-
Industry Canada
-
Canadian Institutes of Health Research (CIHR)
-
Revenue Canada (RC)
-
Health Canada (HC)
-
Treasury Board Of Canada Secretariat (TBS)
-
Senate (Senators)
-
Canadian International Trade Tribunal (CITT)
In-house Corporation Details
Description of activities
AstraZeneca Canada is the 2nd largest research-based pharmaceutical company in Canada. Our unique combination of curiosity and a fundamental commitment to patient health are the key drivers of research and development. Looking beyond the obvious and solving problems innovatively enables our scientists and the researchers we support to discover new and better treatments for a wide array of medical conditions and diseases. In Canada, we invest over CDN$2 million each and every week on research initiatives. Most of our 1,050 Canadian employees work at our high-tech facility in Mississauga, Ontario, headquarters for packaging, clinical research, sales and marketing, and distribution. Over 125 scientists work at our world-class basic pain research centre in Montréal, Québec. AstraZeneca Research & Development Montréal (AZRDM) is a leader in pain control research, focusing primarily on the mechanisms involved in inflammatory and neuropathic pain, the two most common types of chronic pain. Our innovative and extensive product portfolio spans six therapeutic areas: cardiovascular, gastrointestinal, oncology, respiratory, neuroscience and infection.
Responsible officer name and position during the period of this registration
Mark Jones,
President and Chief Executive Officer
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
1004 Middlegate Road
Mississauga, ON L4Y 1M4
Canada
Telephone number:
905-566-7323
Parent Company Information
- AstraZeneca PLC
-
15 Stanhope Gate
London W1K1LN
United Kingdom
Subsidiary Beneficiary Information
AstraZeneca Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- William Charnetski,
Vice President, Corporate Affairs and General Counsel |
Public offices held
- Karen Feltmate,
Vice President, Operations, Business Services & Regulatory Affairs |
No public offices held
- Mark Jones,
President and Chief Executive Officer |
No public offices held
- Catriona McMahon,
Vice President, Medical Affairs |
No public offices held
- Crawford Wright,
Chief Compliance and Privacy Officer |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Tara Bingham,
Federal Government Affairs |
Public offices held
- Claudia Neuber,
Senior Manager, Pricing |
No public offices held